| Not Yet Recruiting | Methotrexate Early Toxicity Monitoring NCT07406230 | Assistance Publique Hopitaux De Marseille | N/A |
| Recruiting | A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PC NCT07350850 | Tongji Hospital | Phase 2 |
| Not Yet Recruiting | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL NCT07185373 | Huashan Hospital | Phase 2 / Phase 3 |
| Recruiting | Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810 | Mayo Clinic | Phase 1 |
| Recruiting | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) NCT07082868 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma NCT06922604 | City of Hope Medical Center | Phase 1 |
| Recruiting | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL NCT06832267 | Zhejiang Cancer Hospital | N/A |
| Recruiting | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL NCT06475235 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV T NCT06541665 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) L NCT05681195 | Baptist Health South Florida | Phase 2 |
| Recruiting | Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complet NCT06175000 | Providence Health & Services | Phase 2 |
| Completed | [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma NCT05390814 | Assistance Publique - Hôpitaux de Paris | Phase 1 |
| Recruiting | Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104) NCT06940791 | Kyorin University | Phase 2 |
| Recruiting | A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL NCT06445257 | Huai'an First People's Hospital | N/A |
| Completed | New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen NCT06115824 | Huashan Hospital | — |
| Recruiting | Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in El NCT06830421 | University Hospital Freiburg | Phase 3 |
| Active Not Recruiting | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Re NCT05485753 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous Syste NCT05135858 | Assistance Publique - Hôpitaux de Paris | Phase 1 |
| Recruiting | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma NCT05600660 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Unknown | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma NCT04845139 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma NCT05351593 | James Rubenstein | Phase 1 / Phase 2 |
| Recruiting | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) NCT05549284 | Affiliated Hospital to Academy of Military Medical Sciences | Phase 2 |
| Not Yet Recruiting | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma NCT05347641 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL NCT05390749 | Peking Union Medical College Hospital | Phase 2 |
| Completed | First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) NCT06454266 | Ningbo No. 1 Hospital | Phase 2 |
| Unknown | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma NCT05334238 | Ruijin Hospital | Phase 3 |
| Active Not Recruiting | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL NCT05036577 | Huashan Hospital | Phase 1 |
| Active Not Recruiting | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma NCT04931368 | Klinikum Stuttgart | Phase 3 |
| Recruiting | Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL NCT04906096 | Lakshmi Nayak, MD | Phase 2 |
| Active Not Recruiting | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma NCT04462328 | Washington University School of Medicine | Phase 1 |
| Unknown | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Cent NCT04831658 | Mingzhi Zhang | Phase 1 / Phase 2 |
| Unknown | Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous Sy NCT04899427 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphom NCT04737889 | Henan Cancer Hospital | Phase 2 |
| Unknown | A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Ne NCT04457869 | Shandong New Time Pharmaceutical Co., LTD | Phase 2 |
| Unknown | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma NCT04514393 | Huiqiang Huang | Phase 2 |
| Recruiting | Pembrolizumab, Ibrutinib and Rituximab in PCNSL NCT04421560 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) NCT04070040 | Beijing Sanbo Brain Hospital | Phase 2 |
| Completed | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma NCT04934579 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Unknown | IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL NCT04066920 | Deok-Hwan Yang | Phase 2 |
| Unknown | Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central N NCT04083066 | Mingzhi Zhang | Phase 4 |
| Unknown | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty NCT04120350 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Completed | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous Syste NCT03495960 | International Extranodal Lymphoma Study Group (IELSG) | Phase 2 |
| Unknown | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT NCT03733327 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Completed | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PC NCT03255018 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma NCT03120000 | PIQUR Therapeutics AG | Phase 2 |
| Unknown | Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma NCT02983942 | Beijing Tiantan Hospital | Phase 1 / Phase 2 |
| Unknown | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Tha NCT03582254 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) NCT02779101 | Prof. Dr. Matthias Preusser | Phase 2 |
| Completed | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma NCT02669511 | PIQUR Therapeutics AG | Phase 2 |
| Unknown | Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiother NCT02655744 | Chang Gung Memorial Hospital | — |
| Unknown | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma NCT02313389 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and NCT02301364 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibruti NCT02203526 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma NCT02113007 | SCRI Development Innovations, LLC | Phase 2 |
| Unknown | MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymph NCT02399189 | Jun Zhu | Phase 2 |
| Terminated | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Le NCT01944943 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym NCT01647971 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumor NCT01421524 | Celgene | Phase 1 |
| Recruiting | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy NCT02657785 | Navy General Hospital, Beijing | Phase 2 / Phase 3 |
| Recruiting | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL NCT02836158 | Navy General Hospital, Beijing | Phase 2 / Phase 3 |
| Withdrawn | Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma NCT00712062 | University of Florida | Phase 2 |
| Active Not Recruiting | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous NCT00863460 | Institut Curie | Phase 2 |
| Unknown | a Phase II Study in Primary Central Nervous System Lymphoma NCT00455286 | National Health Research Institutes, Taiwan | Phase 2 |
| Completed | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma NCT00193973 | Trans Tasman Radiation Oncology Group | Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma NCT00003505 | Burzynski Research Institute | Phase 2 |